Stock Groups

China’s Sinovac COVID-19 booster weaker against Omicron- Hong Kong study -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO A healthcare worker prepares the dose of Sinovac’s coronavirus vaccine (COVID-19), during the mass vaccination of medical personnel at Jakarta’s Istora Senayan Stadium in Jakarta, Indonesia on February 4, 2021. REUTERS/Willy Kurniawan

(Reuters) – Three doses Sinovac CoronaVac COVID-19 vaccine failed to produce sufficient levels of antibodies against the Omicron strain of coronavirus according to Hong Kong researchers.

The analysis showed that the Pfizer BioNTech vaccine proved to be more effective than the Chinese Sinovac vaccine. A third shot of Pfizer BioNTech vaccine, administered following two doses of either the China Sinovac vaccine or the identical vaccine in China provided “protective levels of anti-Omicron antibody.”

Pfizer (NYSE:) BioNTech, its German partner, has claimed that their three-shot course in neutralizing Omicron was effective in laboratory tests.

Researchers from both the University of Hong Kong and Chinese University of Hong Kong conducted the latest study, which was funded by the Health and Medical Research Fund and Government of Hong Kong.

It did not specify how many samples were used for the analysis. Sinovac didn’t immediately reply to our request for comment.

Sinovac’s CoronaVac vaccine and Sinopharm state-owned Sinopharm BBIBP–CorV vaccine are two of the most widely used vaccines in China. They also make up the top COVID-19 vaccines that China exports. Sinopharm also offers a second vaccine for China.

The Sinovac and Pfizer BioNTech shots have been used in Hong Kong. Only people between 12 and 17 years old are eligible for the BioNTech vaccine.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]